164 related articles for article (PubMed ID: 9332313)
1. Immune function in patients with beta thalassaemia receiving the orally active iron-chelating agent deferiprone.
Loebstein R; Dalal I; Nisbet-Brown E; Berkovitch M; Meydan N; Andrews D; Loubser MD; Koren G; Roifman CM; Olivieri NF
Br J Haematol; 1997 Sep; 98(3):597-600. PubMed ID: 9332313
[TBL] [Abstract][Full Text] [Related]
2. Alternate use of deferiprone and desferrioxamine in primary school children with thalassaemia major.
Aydinok Y; Nisli G; Kavakli K
Br J Haematol; 1999 Jul; 106(1):252-3. PubMed ID: 10444196
[No Abstract] [Full Text] [Related]
3. Adherence to desferrioxamine and deferiprone and the impact of deferiprone co-prescription in thalassaemia major patients. Does the addition of deferiprone improve adherence?
Kidson-Gerber G; Lindeman R
Br J Haematol; 2008 Aug; 142(4):679-80. PubMed ID: 18537970
[No Abstract] [Full Text] [Related]
4. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
Kontoghiorghes GJ; Kolnagou A
Lancet; 2003 Jan; 361(9352):184. PubMed ID: 12531621
[No Abstract] [Full Text] [Related]
5. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
Brittenham GM; Nathan DG; Olivieri NF; Pippard MJ; Weatherall DJ
Lancet; 2003 Jan; 361(9352):183; author reply 183-4. PubMed ID: 12531619
[No Abstract] [Full Text] [Related]
6. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry.
Fischer R; Longo F; Nielsen P; Engelhardt R; Hider RC; Piga A
Br J Haematol; 2003 Jun; 121(6):938-48. PubMed ID: 12786807
[TBL] [Abstract][Full Text] [Related]
7. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
St Pierre TG
Lancet; 2003 Jan; 361(9352):182; author reply 183-4. PubMed ID: 12531617
[No Abstract] [Full Text] [Related]
8. Immune and neural status of thalassemic patients receiving deferiprone or combined deferiprone and deferoxamine chelation treatment.
Tourkantoni N; Athanassiou-Metaxa M; Zafiriou D; Tzimouli V; Economou M; Taparkou A; Perifanis V; Kanakoudi-Tsakalidou F
Hemoglobin; 2008; 32(1-2):35-40. PubMed ID: 18274981
[TBL] [Abstract][Full Text] [Related]
9. Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
Kolnagou A; Kontoghiorghe CN; Kontoghiorghes GJ
Drug Res (Stuttg); 2017 Jul; 67(7):404-411. PubMed ID: 28320041
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
Olivieri NF; Brittenham GM; McLaren CE; Templeton DM; Cameron RG; McClelland RA; Burt AD; Fleming KA
N Engl J Med; 1998 Aug; 339(7):417-23. PubMed ID: 9700174
[TBL] [Abstract][Full Text] [Related]
11. Antihistone and other autoantibodies in beta-thalassemia major patients receiving iron chelators.
Pradhan V; Badakere S; Ghosh K
Acta Haematol; 2003; 109(1):35-9. PubMed ID: 12486321
[TBL] [Abstract][Full Text] [Related]
12. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
Fischer R; Engelhardt R
Lancet; 2003 Jan; 361(9352):182-3; author reply 183-4. PubMed ID: 12531618
[No Abstract] [Full Text] [Related]
13. Chromosomal aberration frequencies in patients with thalassaemia major undergoing therapy with deferiprone and deferoxamine in a comparative crossover study.
Marshall R; Tricta F; Galanello R; Leoni G; Kirkland D; Minto S; Spino M
Mutagenesis; 2003 Sep; 18(5):457-63. PubMed ID: 12960415
[TBL] [Abstract][Full Text] [Related]
14. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major.
Borgna-Pignatti C; Cappellini MD; De Stefano P; Del Vecchio GC; Forni GL; Gamberini MR; Ghilardi R; Piga A; Romeo MA; Zhao H; Cnaan A
Blood; 2006 May; 107(9):3733-7. PubMed ID: 16373663
[TBL] [Abstract][Full Text] [Related]
15. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
Barman Balfour JA; Foster RH
Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
[TBL] [Abstract][Full Text] [Related]
16. Immune status of thalassemic patients receiving deferiprone or combined deferiprone and desferrioxamine chelation treatment.
Athanassiou-Metaxa M; Tzimouli V; Economou M; Taparkou A; Tourkantoni N; Kanakoudi-Tsakalidou F
Acta Haematol; 2003; 110(4):224-6. PubMed ID: 14663175
[No Abstract] [Full Text] [Related]
17. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
Pantalone GR; Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Romeo MA; Magnano C; Caruso V; Argento C; Gerardi C; Campisi S; Violi P; Malizia R; Cianciulli P; Rizzo M; D'Ascola DG; Quota A; Prossomariti L; Fidone C; Rigano P; Pepe A; D'Amico G; Morabito A; Gluud C
Hemoglobin; 2011; 35(3):206-16. PubMed ID: 21599433
[TBL] [Abstract][Full Text] [Related]
18. Oral deferiprone for iron chelation in people with thalassaemia.
Roberts DJ; Brunskill SJ; Doree C; Williams S; Howard J; Hyde CJ
Cochrane Database Syst Rev; 2007 Jul; (3):CD004839. PubMed ID: 17636775
[TBL] [Abstract][Full Text] [Related]
19. Sequential use of deferiprone and desferrioxamine in primary school children with thalassaemia major in Turkey.
Aydinok Y; Nisli G; Kavakli K; Coker C; Kantar M; Cetingül N
Acta Haematol; 1999; 102(1):17-21. PubMed ID: 10473883
[TBL] [Abstract][Full Text] [Related]
20. Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major.
Alpendurada F; Smith GC; Carpenter JP; Nair SV; Tanner MA; Banya W; Dessi C; Galanello R; Walker JM; Pennell DJ
J Cardiovasc Magn Reson; 2012 Jan; 14(1):8. PubMed ID: 22277065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
